Acalabrutinib-d3

• UNSPSC Description:

  Acalabrutinib-d3 (ACP-196-d3) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

• Target Antigen:

  Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Field of Research:

  Others

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=NC=CC=C1)C2=CC=C(C=C2)C3=C4C(N)=NC=CN4C([C@@H]5CCCN5C(C#CC([2H])([2H])[2H])=O)=N3

• Molecular Weight:

  468.53

• References & Citations:

  [1]Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21.|[2]Herman SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2016 Nov 30.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported